Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03897348 · ClinicalTrials.gov registry record · Phase 2

Pilot Human Lab Study of Lacosamide in Alcohol Use Disorder (AUD)

A Phase 2 study, sponsored by University of California, San Francisco.

Completed
Registry status
Phase 2
Development phase
4
Enrollment target

NCT03897348 is a Phase 2 study that has completed, run by University of California, San Francisco. The registered enrollment target is 4 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03897348, a Phase 2 study, has completed, sponsored by University of California, San Francisco.

COMPLETED
Registry status
Phase 2
Development phase
4 participants
Enrollment target

Study Summary

The overall goal of the proposed project is to improve the treatment of individuals with AUD. The investigators will conduct the first pilot human laboratory study to assess the effects of two doses of lacosamide on alcohol drinking and craving. The investigators will assess its effects on reducing alcohol intake using a human laboratory method, the Yale Alcohol Drinking Paradigm (ADP). The investigators will also assess the feasibility of the Alcohol Drinking Paradigm (ADP) in order to position our research team to have the capacity to conduct future, larger, hypothesis-testing human laboratory-based experiments designed to test the efficacy of potential alcohol treatments.

Interventions

  • DRUG Placebo
  • DRUG Lacosamide 100 mg
  • DRUG Lacosamide 200 mg

Trial Details

FieldValue
Enrollment Target 4 participants
Start Date 2018-09-17
Est. Completion 2019-06-12
Phase Phase 2

What the Registry Record Tells You About NCT03897348

The ClinicalTrials.gov registry entry for NCT03897348 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT03897348 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03897348 about?

NCT03897348 is a clinical study titled "Pilot Human Lab Study of Lacosamide in Alcohol Use Disorder (AUD)". The overall goal of the proposed project is to improve the treatment of individuals with AUD. The investigators will conduct the first pilot human laboratory study to assess the effects of two doses of lacosamide on alcohol drinking and craving. The investigators will assess its effects on reducing ...

What is the current status of trial NCT03897348?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2018-09-17. Estimated completion is 2019-06-12.

What interventions are being tested in trial NCT03897348?

The interventions under investigation include: Placebo (DRUG), Lacosamide 100 mg (DRUG), Lacosamide 200 mg (DRUG).

Who is sponsoring clinical trial NCT03897348?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.